These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31910388)

  • 1. Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis.
    Spiegel DY; Boyer MJ; Hong JC; Williams CD; Kelley MJ; Salama JK; Palta M
    J Natl Compr Canc Netw; 2020 Jan; 18(1):52-58. PubMed ID: 31910388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration.
    Spiegel DY; Boyer MJ; Hong JC; Williams CD; Kelley MJ; Moore H; Salama JK; Palta M
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):565-573. PubMed ID: 30359718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
    Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
    Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer.
    Polamraju P; Haque W; Verma V; Wiederhold L; Hatch S; Butler EB; Teh BS
    Clin Colorectal Cancer; 2018 Sep; 17(3):e519-e530. PubMed ID: 29753642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis.
    Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
    Oncologist; 2019 Jun; 24(6):803-811. PubMed ID: 29674444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
    BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
    Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
    Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy after neoadjuvant chemoradiation and proctectomy improves survival irrespective of pathologic response in rectal adenocarcinoma: a population-based cohort study.
    Naffouje SA; Liu YJ; Kamarajah SK; Salti GI; Dahdaleh F
    Int J Colorectal Dis; 2022 Oct; 37(10):2137-2148. PubMed ID: 36048196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
    Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
    Cancer; 2017 Mar; 123(5):783-793. PubMed ID: 27780316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.